[1] 张跃伟. 微创介入治疗肝癌对机体免疫功能影响的研究现状与展望. 实用肝脏病杂志,2014,17(3):231-234. [2] Wang R,Chen XZ,Zhang MG,et al.Incidence and mortality of liver cancer in mainland China:changes in first decade of 21st century. Hepatogastroenterology,2015,62(137):118-121. [3] Hirokawa F,Hayashi M,Miyamoto Y,et al.Predictors of poor prognosis by recurrence patterns after curative hepatectomy for hepatocellular carcinoma in Child-Pugh classification A. Hepatogastroenterology,2015,62(137):164-168. [4] Chen JY,Liu L P,Xu JF.Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Onco Targets Ther,2017,10:339-345. [5] Yau T,Tang VY,Yao TJ,et al.Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology,2014,146(7):1691-1700. [6] 中国抗癌协会肝癌专业委员会. 原发性肝癌诊断标准. 中华肝脏病杂志,2000,8(3):135-135. [7] Li A,Ma S,Pawlik T,et al.Surgical treatment of double primary liver cancer:An observational study for a rare type of tumor. Medicine (Baltimore),2016,95(32):e4412. [8] Yoon IS,Shin JH,Han K,et al.Ultrasound-guided intraoperative radiofrequency ablation and surgical resection for liver metastasis from malignant gastrointestinal stromal tumors. Korean J Radiol,2018,19(1):54-62. [9] Ogasawara S,Chiba T,Ooka Y,et al.A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. Plos One,2015,10(4):e0125244. [10] Maeda C,Hidaka E,Mori Y,et al.Tumor diameter is an easy and useful predictor of recurrence in stage II colorectal cancer. Dig Surg,2015,32(5):338-343. [11] De MT,Kuhn E,Dekker LJ,et al.Targeted MS assay predicting tamoxifen resistance in estrogen receptor positive breast cancer tissues and sera. J Proteome Res,2016,15(4):1230-1242. [12] Yan M,Ha J,Aguilar M,et al.Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis,treatment,and long- term survival. J Hepatol,2016,64(2):326-332. [13] Ciria R,López-Cillero P,Gallardo AB,et al.Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma:Modern surgical resection as a feasible alternative to transarterial chemoemolization. Eur J Surg Oncol,2015,41(9):1153-1161. [14] Jun YK,Dong HS,Geum-Youn G,et al.Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clin Mol Hepatol,2016,22(2):250-258. [15] Ko S,Kirihataya Y,Matsumoto Y,et al.Retrocaval liver lifting maneuver and modifications of total hepatic vascular exclusion for liver tumor resection. World J Hepatol,2016,8(8):411-420. [16] Baruah RR, Bhatnaqar V,Aqarwala S,et al.Correlation of pre- and post-operative liver function,duct diameter at porta hepatis, and portal fibrosis with surgical outcomes in biliary atresia. J Indian Assoc Pediatr Surg,2015,20(4):184-188. [17] 程丹,邵志林,吴亮,等. 乙型肝炎肝硬化和肝癌患者血清铁蛋白检测的意义. 实用肝脏病杂志,2016,19(6):736-737. [18] 程亚,李光耀,荚卫东. 成功治疗乙型肝炎相关肝癌患者半肝切除术后凝血障碍1例报道. 实用肝脏病杂志,2016,19(2):233-234. [19] Kaibori M,Ishizaki M,Matsui K,et al.Geriatric assessment as a predictor of postoperative complications in elderly patients with hepatocellular carcinoma. Langenbecks Arch Surg,2016,401(2):205-214. [20] Kudo M,Izumi N,Sakamoto M,et al.Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer,2016,5(3):190-197. |